COMP vs. VRNA

Last updated Jun 9, 2026

COMP (Compass, Inc.) and VRNA (Verona Pharma plc) are both stocks. COMP operates in Software - Application (Technology), while VRNA operates in Biotechnology (Healthcare). At a 0.18 correlation, their price movements are largely independent.

Performance

COMP vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Compass, Inc. (COMP) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

COMP

• 1D: -1.69%
• 1M: -13.07%
• YTD: -28.29%
• 6M: -27.26%
• 1Y: 20.51%
• 3Y*: 29.13%
• 5Y*: -12.67%
• 10Y*: —

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

COMP vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
COMP Compass, Inc.	-28.29%	80.68%	55.59%	61.37%	-74.37%	-57.22%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-19.62%

Correlation

The correlation between COMP and VRNA is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.03
Correlation (3Y) Calculated over the trailing 3-year period	0.18
Correlation (5Y) Calculated over the trailing 5-year period	0.19
Correlation (All Time) Calculated using the full available price history since Apr 1, 2021	0.18

The correlation between COMP and VRNA shifts across timeframes, from 0.03 (1 year) to 0.19 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap COMP : $6.24B VRNA : $9.72B
EPS COMP : $0.02 VRNA : -$0.69
PS Ratio COMP : 0.58 VRNA : 57.97
PB Ratio COMP : 2.21 VRNA : 34.92
Total Revenue (TTM) COMP : $8.31B VRNA : $167.65M
Gross Profit (TTM) COMP : $893.40M VRNA : $159.52M
EBITDA (TTM) COMP : -$177.70M VRNA : -$40.86M

Return for Risk

COMP vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

COMP

COMP Risk / Return Rank: 53
COMP Sharpe Ratio Rank: 54
COMP Sortino Ratio Rank: 54
COMP Omega Ratio Rank: 54
COMP Calmar Ratio Rank: 52
COMP Martin Ratio Rank: 52

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

COMP vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Compass, Inc. (COMP) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	COMP	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	0.33	—	—
Sortino ratio: Return per unit of downside risk	0.97	—	—
Omega ratio: Gain probability vs. loss probability	1.12	—	—
Calmar ratio: Return relative to maximum drawdown	0.41	—	—
Martin ratio: Return relative to average drawdown	0.86	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	COMP	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.33	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.16	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.22	—	—

Drawdowns

Drawdown Indicators

	COMP	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-90.82%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-50.81%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-57.24%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-89.25%	—	—
Current Drawdown Current decline from peak	-62.38%	—	—
Average Drawdown Average peak-to-trough decline	-66.53%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	23.81%	—	—

Volatility

Volatility by Period

	COMP	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.24%	—	—
Volatility (6M) Calculated over the trailing 6-month period	50.82%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	63.40%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	79.89%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.07%	—	—

Dividends

COMP vs. VRNA - Dividend Comparison

Neither COMP nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

COMP vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Compass, Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

COMP - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Compass, Inc. reported a gross profit of 0.00 and revenue of 2.70B. Therefore, the gross margin over that period was 0.0%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

COMP - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Compass, Inc. reported an operating income of -351.00M and revenue of 2.70B, resulting in an operating margin of -13.0%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

COMP - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Compass, Inc. reported a net income of 22.00M and revenue of 2.70B, resulting in a net margin of 0.8%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both COMP and VRNA in my portfolio?

COMP and VRNA have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.